Clinical trials: Ovarian, Fallopian, and Primary Peritoneal Cancer
Ovarian Cancer, Fallopian Tube Adenocarcinoma
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors
Many individuals with ovarian cancer experience distress, fatigue, weakness, anxiety, and other symptoms that decrease quality of life.
- Conditions
- Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma
- Trial name
- NCT03641287
- Testing
- Exercise Counseling, Aerobic Exercise, Physiological Support
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Washington
Ovarian Cancer, Ovarian Neoplasm
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel [C/P]) and continued as…
- Trial name
- VELIA (NCT02470585)
- Testing
- Veliparib, Paclitaxel, Carboplatin
- Where
- 210 sites in United States, Australia and 9 more
- Volunteers
- 1,140 people
- Sponsor
- AbbVie
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
This randomized phase III trial studies paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial, peritoneal cancer, or…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00108745
- Testing
- Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 315 sites in United States
- Volunteers
- 1,157 people
- Sponsor
- GOG Foundation
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of gynecological malignancy-related deaths worldwide and is a substantial health threat to women.
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- Trientine (NCT03480750)
- Testing
- trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin
- Volunteers
- 18 people
- Sponsor
- National Cheng-Kung University Hospital
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT02713386
- Testing
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate
- Where
- 110 sites in United States
- Volunteers
- 147 people
- Sponsor
- NRG Oncology
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well pemetrexed disodium and carboplatin work in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01001910
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Albert Einstein College of Medicine
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01716715
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 173 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients
The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at…
- Trial name
- NCT01579812
- Testing
- Metformin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Michigan Rogel Cancer Center
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms, Fallopian Tube Neoplasms
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Background: The best treatment for ovarian and related female reproductive tract cancers is not yet known for patients whose disease has not responded to or has recurred after standard treatment.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
- Trial name
- NCT01313078
- Testing
- Pegylated L-Asparaginase
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of niraparib in participants with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 3 or 4…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03759600
- Testing
- Niraparib
- Where
- 33 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Takeda
Ovarian Cancer, Fallopian Tube Cancer
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- EUDARIO (NCT03783949)
- Testing
- Ganetespib, Niraparib, Carboplatin
- Where
- 13 sites in Austria, Belgium and 3 more
- Volunteers
- 122 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ovarian Cancer, Fallopian Tube Cancer
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00343044
- Testing
- Topotecan, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer
- Trial name
- NCT03188432
- Testing
- Carboplatin, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
This phase II trial is studying how well SJG-126 works in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that did not respond to previous treatment with cisplatin or carboplatin.
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT01200797
- Testing
- SJG-136, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- ARTISTRY-7 (NCT05092360)
- Testing
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 456 people
- Sponsor
- Mural Oncology, Inc